The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral Mucositis Drugs for Cancer Therapy Market Research Report 2025
Synopsis
Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
Global Oral Mucositis Drugs for Cancer Therapy market is projected to reach US$ 281.5 million in 2029, increasing from US$ 179.4 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Mucositis Drugs for Cancer Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral Mucositis Drugs for Cancer Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
3M Healthcare
GSK
Pfizer
Colgate-Palmolive
Norgine
Sobi
Bausch Health
EUSA Pharma
Camurus
Clinigen Group
Helsinn Healthcare
Alliance Pharma
Segment by Type
Mouthwash
Pain Control Medication
Other
Segment by Application
Chemotherapy
Radiotherapy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Oral Mucositis Drugs for Cancer Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
Global Oral Mucositis Drugs for Cancer Therapy market is projected to reach US$ 281.5 million in 2029, increasing from US$ 179.4 million in 2022, with the CAGR of 5.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Mucositis Drugs for Cancer Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral Mucositis Drugs for Cancer Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
3M Healthcare
GSK
Pfizer
Colgate-Palmolive
Norgine
Sobi
Bausch Health
EUSA Pharma
Camurus
Clinigen Group
Helsinn Healthcare
Alliance Pharma
Segment by Type
Mouthwash
Pain Control Medication
Other
Segment by Application
Chemotherapy
Radiotherapy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Oral Mucositis Drugs for Cancer Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Oral Mucositis Drugs for Cancer Therapy Market Overview
1.1 Product Overview and Scope of Oral Mucositis Drugs for Cancer Therapy
1.2 Oral Mucositis Drugs for Cancer Therapy Segment by Type
1.2.1 Global Oral Mucositis Drugs for Cancer Therapy Market Value Comparison by Type (2023-2029)
1.2.2 Mouthwash
1.2.3 Pain Control Medication
1.2.4 Other
1.3 Oral Mucositis Drugs for Cancer Therapy Segment by Application
1.3.1 Global Oral Mucositis Drugs for Cancer Therapy Market Value by Application: (2023-2029)
1.3.2 Chemotherapy
1.3.3 Radiotherapy
1.4 Global Oral Mucositis Drugs for Cancer Therapy Market Size Estimates and Forecasts
1.4.1 Global Oral Mucositis Drugs for Cancer Therapy Revenue 2018-2029
1.4.2 Global Oral Mucositis Drugs for Cancer Therapy Sales 2018-2029
1.4.3 Global Oral Mucositis Drugs for Cancer Therapy Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Oral Mucositis Drugs for Cancer Therapy Market Competition by Manufacturers
2.1 Global Oral Mucositis Drugs for Cancer Therapy Sales Market Share by Manufacturers (2018-2023)
2.2 Global Oral Mucositis Drugs for Cancer Therapy Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Oral Mucositis Drugs for Cancer Therapy Average Price by Manufacturers (2018-2023)
2.4 Global Oral Mucositis Drugs for Cancer Therapy Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Oral Mucositis Drugs for Cancer Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Mucositis Drugs for Cancer Therapy, Product Type & Application
2.7 Oral Mucositis Drugs for Cancer Therapy Market Competitive Situation and Trends
2.7.1 Oral Mucositis Drugs for Cancer Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Mucositis Drugs for Cancer Therapy Players Market Share by Revenue
2.7.3 Global Oral Mucositis Drugs for Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Mucositis Drugs for Cancer Therapy Retrospective Market Scenario by Region
3.1 Global Oral Mucositis Drugs for Cancer Therapy Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Oral Mucositis Drugs for Cancer Therapy Global Oral Mucositis Drugs for Cancer Therapy Sales by Region: 2018-2029
3.2.1 Global Oral Mucositis Drugs for Cancer Therapy Sales by Region: 2018-2023
3.2.2 Global Oral Mucositis Drugs for Cancer Therapy Sales by Region: 2024-2029
3.3 Global Oral Mucositis Drugs for Cancer Therapy Global Oral Mucositis Drugs for Cancer Therapy Revenue by Region: 2018-2029
3.3.1 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Region: 2018-2023
3.3.2 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Region: 2024-2029
3.4 North America Oral Mucositis Drugs for Cancer Therapy Market Facts & Figures by Country
3.4.1 North America Oral Mucositis Drugs for Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Oral Mucositis Drugs for Cancer Therapy Sales by Country (2018-2029)
3.4.3 North America Oral Mucositis Drugs for Cancer Therapy Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Oral Mucositis Drugs for Cancer Therapy Market Facts & Figures by Country
3.5.1 Europe Oral Mucositis Drugs for Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Oral Mucositis Drugs for Cancer Therapy Sales by Country (2018-2029)
3.5.3 Europe Oral Mucositis Drugs for Cancer Therapy Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Mucositis Drugs for Cancer Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Mucositis Drugs for Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Oral Mucositis Drugs for Cancer Therapy Sales by Country (2018-2029)
3.6.3 Asia Pacific Oral Mucositis Drugs for Cancer Therapy Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Oral Mucositis Drugs for Cancer Therapy Market Facts & Figures by Country
3.7.1 Latin America Oral Mucositis Drugs for Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Oral Mucositis Drugs for Cancer Therapy Sales by Country (2018-2029)
3.7.3 Latin America Oral Mucositis Drugs for Cancer Therapy Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Mucositis Drugs for Cancer Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Mucositis Drugs for Cancer Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Oral Mucositis Drugs for Cancer Therapy Sales by Country (2018-2029)
3.8.3 Middle East and Africa Oral Mucositis Drugs for Cancer Therapy Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Oral Mucositis Drugs for Cancer Therapy Sales by Type (2018-2029)
4.1.1 Global Oral Mucositis Drugs for Cancer Therapy Sales by Type (2018-2023)
4.1.2 Global Oral Mucositis Drugs for Cancer Therapy Sales by Type (2024-2029)
4.1.3 Global Oral Mucositis Drugs for Cancer Therapy Sales Market Share by Type (2018-2029)
4.2 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Type (2018-2029)
4.2.1 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Type (2018-2023)
4.2.2 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Type (2024-2029)
4.2.3 Global Oral Mucositis Drugs for Cancer Therapy Revenue Market Share by Type (2018-2029)
4.3 Global Oral Mucositis Drugs for Cancer Therapy Price by Type (2018-2029)
5 Segment by Application
5.1 Global Oral Mucositis Drugs for Cancer Therapy Sales by Application (2018-2029)
5.1.1 Global Oral Mucositis Drugs for Cancer Therapy Sales by Application (2018-2023)
5.1.2 Global Oral Mucositis Drugs for Cancer Therapy Sales by Application (2024-2029)
5.1.3 Global Oral Mucositis Drugs for Cancer Therapy Sales Market Share by Application (2018-2029)
5.2 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Application (2018-2029)
5.2.1 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Application (2018-2023)
5.2.2 Global Oral Mucositis Drugs for Cancer Therapy Revenue by Application (2024-2029)
5.2.3 Global Oral Mucositis Drugs for Cancer Therapy Revenue Market Share by Application (2018-2029)
5.3 Global Oral Mucositis Drugs for Cancer Therapy Price by Application (2018-2029)
6 Key Companies Profiled
6.1 3M Healthcare
6.1.1 3M Healthcare Corporation Information
6.1.2 3M Healthcare Description and Business Overview
6.1.3 3M Healthcare Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.1.4 3M Healthcare Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.1.5 3M Healthcare Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Colgate-Palmolive
6.4.1 Colgate-Palmolive Corporation Information
6.4.2 Colgate-Palmolive Description and Business Overview
6.4.3 Colgate-Palmolive Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Colgate-Palmolive Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.4.5 Colgate-Palmolive Recent Developments/Updates
6.5 Norgine
6.5.1 Norgine Corporation Information
6.5.2 Norgine Description and Business Overview
6.5.3 Norgine Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Norgine Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.5.5 Norgine Recent Developments/Updates
6.6 Sobi
6.6.1 Sobi Corporation Information
6.6.2 Sobi Description and Business Overview
6.6.3 Sobi Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sobi Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.6.5 Sobi Recent Developments/Updates
6.7 Bausch Health
6.6.1 Bausch Health Corporation Information
6.6.2 Bausch Health Description and Business Overview
6.6.3 Bausch Health Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bausch Health Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.7.5 Bausch Health Recent Developments/Updates
6.8 EUSA Pharma
6.8.1 EUSA Pharma Corporation Information
6.8.2 EUSA Pharma Description and Business Overview
6.8.3 EUSA Pharma Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.8.4 EUSA Pharma Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.8.5 EUSA Pharma Recent Developments/Updates
6.9 Camurus
6.9.1 Camurus Corporation Information
6.9.2 Camurus Description and Business Overview
6.9.3 Camurus Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Camurus Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.9.5 Camurus Recent Developments/Updates
6.10 Clinigen Group
6.10.1 Clinigen Group Corporation Information
6.10.2 Clinigen Group Description and Business Overview
6.10.3 Clinigen Group Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Clinigen Group Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.10.5 Clinigen Group Recent Developments/Updates
6.11 Helsinn Healthcare
6.11.1 Helsinn Healthcare Corporation Information
6.11.2 Helsinn Healthcare Oral Mucositis Drugs for Cancer Therapy Description and Business Overview
6.11.3 Helsinn Healthcare Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Helsinn Healthcare Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.11.5 Helsinn Healthcare Recent Developments/Updates
6.12 Alliance Pharma
6.12.1 Alliance Pharma Corporation Information
6.12.2 Alliance Pharma Oral Mucositis Drugs for Cancer Therapy Description and Business Overview
6.12.3 Alliance Pharma Oral Mucositis Drugs for Cancer Therapy Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Alliance Pharma Oral Mucositis Drugs for Cancer Therapy Product Portfolio
6.12.5 Alliance Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Mucositis Drugs for Cancer Therapy Industry Chain Analysis
7.2 Oral Mucositis Drugs for Cancer Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Mucositis Drugs for Cancer Therapy Production Mode & Process
7.4 Oral Mucositis Drugs for Cancer Therapy Sales and Marketing
7.4.1 Oral Mucositis Drugs for Cancer Therapy Sales Channels
7.4.2 Oral Mucositis Drugs for Cancer Therapy Distributors
7.5 Oral Mucositis Drugs for Cancer Therapy Customers
8 Oral Mucositis Drugs for Cancer Therapy Market Dynamics
8.1 Oral Mucositis Drugs for Cancer Therapy Industry Trends
8.2 Oral Mucositis Drugs for Cancer Therapy Market Drivers
8.3 Oral Mucositis Drugs for Cancer Therapy Market Challenges
8.4 Oral Mucositis Drugs for Cancer Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
